bluebird reports updated LentiGlobin data, 3Q17 earnings

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in two patients receiving the therapy in the Phase I HGB-206 trial to treat severe sickle cell disease.

LentiGlobin BB305 comprises autologous CD34+ stem cells transduced ex vivo with a lentiviral vector delivering the human beta globin gene. The announcement came ahead of the company's planned presentations next month at the American Society of Hematology meeting in Atlanta. Abstracts from the conference were published Wednesday morning...